On The Threshold Of The Tumor Microenvironment
This article was originally published in Pharmaceutical Approvals Monthly
Threshold Pharmaceuticals’ lead compound from its hypoxia-activated prodrug platform, TH-302, is partnered with Merck KGaA on one Phase III program and in internal development for another Phase III.
You may also be interested in...
Threshold And Molecular Templates Merge To Test The Power Of Two
Although a vehicle for Molecular Templates to take its Engineered Toxin Bodies oncology platform public, the combined company also will seek a pathway to approval for Threshold's evofosfamide for pancreatic cancer in Japan.
Where Merck KGAA’s Pipeline Stands
Pipeline review resulted in new focus and products with high value, exec explains.
Merck Serono Says Partnering Part Of Its Future, Seeks Anti-PD-L1 Deal
Mid-sized German pharma says partnering will be part of its future, as it progresses three key pipeline assets and initiates talks with big pharma players wanting to partner its anti-PD-L1 compound.